CTOs on the Move

FirstString Research Inc

www.firststringresearch.com

 
FirstString Research was founded on a vision to deliver clinically relevant and effective solutions for the treatment of diseases based upon insights and understanding from the molecular and cellular contexts that define the underlying pathology.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

FirstString Research Inc raised $11.7M on 04/22/2019
FirstString Research Inc raised $26.7M on 04/21/2021

Similar Companies

Vybion

Vybion is a Ithaca, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.

ONI

ONI is a pioneer of next generation super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world`s first benchtop sized super-resolution microscope, delivers a step change in usability and precision. The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal. The company`s achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard. ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. We have a vision for making high tech science available to anyone, anywhere, from the research bench to your doctor`s office.

BlueSphere Bio

Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…

Renalytix

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.